Cargando…
Immunotherapies for the Treatment of Uveal Melanoma—History and Future
Background: Uveal melanoma is the most common primary intraocular malignancy among adults. It is, nevertheless, a rare disease, with an incidence of approximately one case per 100,000 individuals per year in Europe. Approximately half of tumors will eventually metastasize, and the liver is the organ...
Autores principales: | Schank, Timo E., Hassel, Jessica C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721437/ https://www.ncbi.nlm.nih.gov/pubmed/31344957 http://dx.doi.org/10.3390/cancers11081048 |
Ejemplares similares
-
TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma
por: Strobel, Sophia B., et al.
Publicado: (2022) -
Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?
por: Castet, Florian, et al.
Publicado: (2019) -
Recent Advances and Challenges in Uveal Melanoma Immunotherapy
por: Fu, Yihang, et al.
Publicado: (2022) -
S100 as Serum Tumor Marker in Advanced Uveal Melanoma
por: Salzmann, Martin, et al.
Publicado: (2023) -
Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)